ADVERTISEMENT

COVID-19 vaccine safe for kids -- Gov. Fernando

Published Feb 10, 2022 07:12 am


Bulacan Gov. Daniel R. Fernando assured that the specially formulated COVID-19 vaccine for children, five to 11 years old, is safe as the provincial government rolled out its Resbakuna Kids pediatric vaccination program at the Hiyas ng Bulacan Convention Center in the City of Malolos on Wednesday, Feb. 9.

THUMBS UP -- Marcus Julian C. Mendoza, 11, shows a thumbs up while receiving his Pfizer vaccine administered by Department of Health-Region 3 Regional Director Corazon I. Flores during the Resbakuna Kids Launching COVID-19 Pediatric Vaccination at the Bulacan Provincial Vaccination Site, Hiyas ng Bulacan Convention Center, City of Malolos, Bulacan on Wednesday, Feb. 9, 2022. Also in photo are (from left): Marcus’ father Fiscal Marcelo SP. Mendoza, his sister Zena Grace C. Mendoza, National Task Force Against COVID-19 Chief Implementer and Vaccine Czar Sec. Carlito G. Galvez, Jr., Bulacan Governor Daniel R. Fernando, Board Member Alexis Castro, Provincial Health Officer II Dr. Hjordis Marushka Celis, Marcus' mother, and Provincial Administrator Antonia Constantino. (Photo courtesy of Provincial Public Affairs Office)

Pfizer vaccine doses were administered to a total of 200 children. Pfizer is the only vaccine that received emergency use approval from the Food and Drug Administration (FDA) for the five to 11 age bracket.

According to National Task Force Against COVID-19 Chief Implementer and vaccine czar Secretary Carlito G. Galvez, Jr., the Pfizer vaccines were reformulated to minimize adverse effects on children.

“Para mawala ‘yung takot ng mga magulang, mayroon na tayong nabakunahan na more or less 20,000. Nakikita natin na very safe itong Pfizer dahil unang una, nagdaan ito ng matagal na ekperimentasyon at mga trials; at itong reformulated vaccines na ito may 10 micrograms lamang upang mabawasan ‘yung adverse effects nito,” (To allay the fears of parents, we have already inoculated more or less 20,000 children and we have observed that Pfizer is very safe. It was approved after a series of trials and this reformulated vaccine only has 10 micrograms to minimize the advese effects)," Galvez said.

Fernando said he understands the concern of parents for the safety of their children and assured them that pediatric vaccination is needed as the country prepares for the resumption of face-to-face classes.

He said the vaccine is safe for young people with comorbidities since it onlyhas mild side effects. Children with medical conditions such as medical complexity, genetic, neurologic conditions, metabolic/endocrine disease, cardiovascular disease, obesity, tuberculosis, renal disorder, lung disease, and those who are immunocompromised are required to consult their doctors and present the necessary medical certificates.

ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ articles_filter_1564_widget.title }}

.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });

Sign up by email to receive news.